MARKET

REGN

REGN

Regeneron Pharmaceuticals
NASDAQ
1,036.52
+9.97
+0.97%
After Hours: 1044.78 +8.26 +0.80% 19:46 06/14 EDT
OPEN
1,024.30
PREV CLOSE
1,026.55
HIGH
1,042.66
LOW
1,017.96
VOLUME
353.92K
TURNOVER
0
52 WEEK HIGH
1,042.66
52 WEEK LOW
684.81
MARKET CAP
114.21B
P/E (TTM)
30.61
1D
5D
1M
3M
1Y
5Y
Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting
Seeking Alpha · 1h ago
UPDATED LINVOSELTAMAB DATA SHOWCASE CONTINUED DEEPENING OF RESPONSES IN PATIENTS WITH HEAVILY PRE-TREATED MULTIPLE MYELOMA
Reuters · 2h ago
REGENERON PHARMACEUTICALS: AT 14-MONTHS MEDIAN FOLLOW-UP IN TRIAL, 50% OF PATIENTS ACHIEVED A COMPLETE RESPONSE OR BETTER, A 71% OVERALL RESPONSE RATE
Reuters · 2h ago
Ocular Therapeutix jumps after investor day updates
Shares of Ocular Therapeutix jumped after investor day updates. The eyecare specialist highlighted advances in its SOL-1 Phase 3 trial for its wet AMD candidate Axpaxli. With 60 trial sites and 151 subjects involved, the study is expected to be completed by 2024.
Seeking Alpha · 1d ago
Regeneron wins injunction blocking Samsung Bioepis from launching generic Eylea
Seeking Alpha · 1d ago
Benjamin Graham Detailed Fundamental Analysis - REGN
NASDAQ · 1d ago
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
NASDAQ · 1d ago
Structure Therapeutics: Yet Another Potential GLP-1 Entrant
Structure Therapeutics Inc. Shares surged over 50% on positive GSBR-1290 data, competing with other oral GLP-1R clinical rivals. The company used the spike in the stock to raise additional capital. Shares of Structure Therapeutic Inc. Rallied over 50%. Structure is developing a drug for the treatment of type II diabetes and obesity. Its efficacy at week 12 fell below Novo Nordisk's amycretin but still competitive in the obesity treatment landscape.
Seeking Alpha · 1d ago
More
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.

Webull offers Regeneron Pharmaceuticals Inc stock information, including NASDAQ: REGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading REGN stock methods without spending real money on the virtual paper trading platform.